Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest Financial Results

Q2 2019

Quarter Ended Jun 30, 2019

Latest 10-K

View Latest 10-K

Stock Information

Symbol

Nasdaq: CWBR

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.

AGM Investor Presentation

AGM Investor Presentation

Download

Leadership

Our scientific and management teams are our backbone, providing experience and proven success.

Investor Contact Information

Company

CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park, CA 94025
T: (650) 446-7888

Investor Relations

Jon Stern, COO
Investor Relations
T: (650) 446-7888
jon.stern@cohbar.com

Transfer Agent

American Stock Transfer & Trust Company (Canada)
1066 West Hastings Street
Suite 1600
Vancouver, BC V6E 3X1